Haitong Securities(600837) 证券之星·2025-03-30 10:17Summary of Key Points Core Viewpoint - The company has completed the investment project "Annual Production of 1,000kg Antibody Industrialization Construction Project" and plans to permanently supplement its working capital with the remaining raised funds, which aligns with its operational needs and long-term development strategy [9][10]. Fundraising Basic Information - The total amount raised by the company was RMB 3,476,520,000, with a net amount of RMB 3,303,432,172.40, all of which was received by January 10, 2022 [1][2]. Fund Management and Usage - The company established special accounts for managing the raised funds, which are stored in accounts approved by the board of directors, ensuring investor protection [2]. - As of February 28, 2025, the remaining balance of the raised funds for the "Annual Production of 1,000kg Antibody Industrialization Construction Project" was RMB 29,204,764.93 [4][6]. Project Completion and Fund Surplus - The project has been completed as of December 31, 2024, and the remaining funds will be used to enhance operational efficiency [6][9]. - The surplus funds amounting to RMB 18,944.20 million will be permanently added to the working capital [10]. Reasons for Fund Surplus - The surplus was primarily due to prudent fund management, effective cost control, and the use of self-owned funds and bank loans for project expenses, leading to a certain amount of surplus [7][9]. Future Fund Usage Plan - The company plans to use the surplus funds to support daily operations, ensuring efficient use of the raised funds [8][10]. Review and Approval Process - The decision to conclude the investment project and reallocate surplus funds has been approved by the board of directors and the supervisory board, and will be submitted for shareholder meeting approval [10][11].